Status:
UNKNOWN
Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis
Lead Sponsor:
University of Parma
Conditions:
Retroperitoneal Fibrosis
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Idiopathic retroperitoneal fibrosis (IRF) is a rare disease characterised by the presence of a retroperitoneal periaortic fibro-inflammatory tissue which may entrap the ureters and cause renal failure...
Detailed Description
Idiopathic retroperitoneal fibrosis (IRF) is a rare condition hallmarked by the presence of a retroperitoneal mass consisting of chronic inflammatory infiltrate and abundant fibrous tissue. IRF usuall...
Eligibility Criteria
Inclusion
- Diagnosis of idiopathic or perianeurismal retroperitoneal fibrosis
Exclusion
- Previously treated patients; retroperitoneal fibrosis secondary to drugs(e.g. methysergide, methyldopa, pergolide, ergot alkaloids), infections (e.g. tuberculosis), cancer (e.g. lymphoma, sarcoma), radiotherapy, trauma, major surgery, systemic connective tissue or vasculitis disease (e.g. SLE, panarteritis nodosa); pregnancy; active infections or tumours; known hypersensitivity to prednisone or tamoxifen; uncontrolled diabetes.
Key Trial Info
Start Date :
October 1 2000
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00440349
Start Date
October 1 2000
End Date
April 1 2007
Last Update
February 27 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical Medicine Nephrology and Health Science, Parma University Hospital
Parma, Parma, Italy, 43100